1. Home
  2. NRIX vs KRO Comparison

NRIX vs KRO Comparison

Compare NRIX & KRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • KRO
  • Stock Information
  • Founded
  • NRIX 2009
  • KRO 1916
  • Country
  • NRIX United States
  • KRO United States
  • Employees
  • NRIX N/A
  • KRO N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • KRO Major Chemicals
  • Sector
  • NRIX Health Care
  • KRO Industrials
  • Exchange
  • NRIX Nasdaq
  • KRO Nasdaq
  • Market Cap
  • NRIX 728.6M
  • KRO 598.2M
  • IPO Year
  • NRIX 2020
  • KRO N/A
  • Fundamental
  • Price
  • NRIX $10.69
  • KRO $5.42
  • Analyst Decision
  • NRIX Strong Buy
  • KRO Strong Sell
  • Analyst Count
  • NRIX 14
  • KRO 2
  • Target Price
  • NRIX $29.07
  • KRO $7.75
  • AVG Volume (30 Days)
  • NRIX 1.2M
  • KRO 323.7K
  • Earning Date
  • NRIX 10-09-2025
  • KRO 11-05-2025
  • Dividend Yield
  • NRIX N/A
  • KRO 3.64%
  • EPS Growth
  • NRIX N/A
  • KRO 3452.79
  • EPS
  • NRIX N/A
  • KRO 0.59
  • Revenue
  • NRIX $88,381,000.00
  • KRO $1,892,000,000.00
  • Revenue This Year
  • NRIX $74.59
  • KRO $4.87
  • Revenue Next Year
  • NRIX N/A
  • KRO $8.34
  • P/E Ratio
  • NRIX N/A
  • KRO $9.37
  • Revenue Growth
  • NRIX 41.86
  • KRO 6.51
  • 52 Week Low
  • NRIX $8.18
  • KRO $4.70
  • 52 Week High
  • NRIX $29.56
  • KRO $12.98
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 63.25
  • KRO 37.59
  • Support Level
  • NRIX $8.20
  • KRO $5.56
  • Resistance Level
  • NRIX $10.23
  • KRO $5.89
  • Average True Range (ATR)
  • NRIX 0.50
  • KRO 0.21
  • MACD
  • NRIX 0.27
  • KRO -0.04
  • Stochastic Oscillator
  • NRIX 99.80
  • KRO 6.25

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About KRO Kronos Worldwide Inc

Kronos Worldwide Inc manufactures and sells titanium dioxide pigments. Titanium dioxide is a white inorganic pigment used in various products. The majority of Kronos' sales come from titanium dioxide used for coatings on automobiles, aircraft, machines, appliances, traffic paint, and in both commercial and residential interiors and exteriors. The second product category is titanium dioxide used for plastics such as packaging materials and food packaging, houseware, appliances, toys, and computer cases. The majority of revenue comes from the United States.

Share on Social Networks: